Albireo Pharma, Inc. ALBO Income Statement

Albireo pharma, inc. (ALBO)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Jun'10
Revenue
10,615	9,636	3,776	2,628	2,108	12,740	0	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue
-	-	-	-	-	-	-	-	-	-	-	-	11,241	11,364	8,125	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Operating expenses:
Revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Research and development
53,376	45,575	40,863	38,533	33,910	31,732	26,219	19,779	16,330	12,991	10,705	9,541	9,292	8,077	7,966	7,891	10,232	11,552	13,365	13,946	12,520	13,860	14,194	14,806	14,652	13,361	14,296	15,479	14,961	14,638	12,315	10,201	10,186	10,445	13,597	17,238	0	0	0
Government grants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	531	827	625	447	546	0	0	0	-	-	0	0	-	-	-	-	-
General and administrative
25,823	22,963	22,633	20,473	19,226	18,061	16,828	16,687	16,162	15,246	20,740	18,377	17,692	15,786	7,312	7,399	5,896	6,201	6,402	6,092	5,915	6,035	5,598	5,947	6,367	6,810	6,843	6,817	6,825	6,481	7,072	7,987	8,593	9,068	9,625	10,044	0	0	0
Other operating expense, net
-6,730	-2,210	-5,779	-1,150	-1,629	-837	1,890	1,677	2,229	3,659	790	331	-24	205	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
85,929	70,748	69,275	60,156	54,765	50,630	41,157	34,789	30,263	24,578	30,655	27,587	27,008	23,658	15,471	15,425	15,973	17,753	19,767	20,038	18,208	19,461	19,261	19,926	20,394	19,724	20,593	21,958	21,473	20,835	19,299	18,188	18,779	19,513	23,222	27,282	0	0	0
Operating loss
-75,314	-61,112	-65,499	-57,528	-52,657	-37,890	-28,989	-22,858	-19,061	-24,577	-27,414	-24,318	-15,767	-12,294	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense, net
-5,925	-5,296	-4,723	-4,816	-5,131	-4,838	-3,631	-2,241	-727	40	-151	-682	-1,042	-1,319	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-operating income (expense), net
-	-	-	-	-	-3,363	-2,471	-2,478	638	335	-2,951	-3,035	-2,911	-2,675	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	264	267	273	60	52	43	36	42	49	57	57	56	56	63	67	72	80	86	91	79	60	33	0	0	0
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-	0	0	-	-
Adjustments to fair value of common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	176	299	465	1,009	2,230	3,659	3,067	5,107	7,244	1,265	1,575	1,217	-2,475	601	863	-1,510	7,367	10,077	9,694	12,611	0	0	0	-
Loss on settlement of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-	0	-	-	-
Net loss before income taxes
-	-	-	-	-	-	-	-	-19,150	-24,202	-30,516	-28,035	-19,720	-16,288	-8,337	-7,533	-16,114	-17,230	-18,708	-17,765	-14,513	-16,352	-14,105	-12,625	-19,072	-18,093	-19,320	-24,370	-20,805	-19,900	-20,729	-10,735	-8,611	-9,740	-10,551	-23,359	0	0	0
Income tax
-	-	-	-	-	-	-	-	212	212	62	62	62	62	8	14	34	35	29	26	20	23	26	35	15	16	15	29	14	15	18	1	48	45	41	-6	0	0	0
Net loss
-77,548	-62,717	-71,059	-63,174	-61,149	-46,111	-35,303	-27,789	-19,362	-24,414	-30,578	-28,097	-19,782	-16,350	-8,345	-7,547	-16,148	-17,265	-18,737	-17,791	-14,533	-16,375	-14,131	-12,660	-19,087	-18,109	-19,335	-24,399	-20,819	-19,915	-20,747	-10,736	-8,659	-9,785	-10,592	0	0	0	-
Net loss per share - basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13.32	7.42	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share - diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13.32	0.69	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares outstanding - basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	302	288	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares outstanding - diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	302	3,101	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share attributable to holders of common stock:
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Charge for accretion of beneficial conversion rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-	0	-	-	-
Deemed dividend - warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-	0	-	-	-
Net loss applicable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20,819	-19,915	-20,747	-10,736	-8,659	-9,785	-10,592	-23,353	0	0	0
Net loss per common share - basic and diluted
-2.23	-0.57	-1.73	-1.35	-1.39	-1.40	-1.17	-1.22	-0.15	-0.47	-0.73	-0.86	-1.06	-6.79	-6.26	12.06	-12.20	-0.05	-13.20	-0.12	-0.18	-0.20	-0.10	-0.15	-0.29	-0.12	0.05	-0.66	-0.37	-0.26	-0.47	-0.52	-0.45	-0.47	-0.47	-0.48	-0.21	-0.20	-0.36
Weighted-average shares outstanding:
Weighted-average common shares used to compute basic and diluted net loss per common share
14,132	12,708	12,685	12,355	12,001	12,006	11,969	11,938	10,896	8,934	8,878	7,171	6,292	60,007	-183,340	128,026	265	63,583	-96,229	53,893	24,369	23,435	22,341	21,118	21,083	21,073	19,670	14,573	14,182	14,176	12,568	11,600	9,688	9,673	-	8,254	26,469	-	-
Weighted average shares outstanding - basic and diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26,419	23,944